Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Rezolute, Inc. (RZLT)

Rezolute Q1 net loss $18.5 million; upLIFT tumor HI topline due mid-December

Mixed Impact 3 of 5 earnings Written later

Rezolute reported first quarter fiscal 2027 results for the quarter ended September 30, 2026, with a net loss of $18.5 million, compared with $18.2 million a year earlier, and cash and investments of $90.0 million, down from $107.8 million at June 30, 2026. The company expects topline results from its Phase 3 upLIFT tumor HI study by mid-December 2026 and plans to submit a BLA for ersodetug in 2027, but the congenital HI sunRIZE study did not meet its primary endpoint, and FDA's support for a filing does not guarantee approval.

Key points

  • Net loss was $18.5 million, or $0.18 per share, versus $18.2 million, or $0.18 per share, a year earlier.
  • Cash, cash equivalents and marketable investments were $90.0 million at September 30, 2026, down from $107.8 million at June 30, 2026.
  • upLIFT tumor HI topline results are expected by mid-December 2026.
  • FDA recommended a BLA for congenital HI after a pre-BLA meeting, though the sunRIZE primary endpoint was not statistically significant.

The filing

CompanyRezolute, Inc. (RZLT)
Form8-K, current report
Filed with the SECNov 5, 2026, 4:14 PM ET
Accession number0001104659-26-123336

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:38 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.